Add to Watchlist
View Current for MREO
View SuperFeed for MREO
View Charts for MREO
Add or remove $MREO from your watchlists:
Hang tight! We're updating your watchlist data. This might take a minute...
You have not created a stock watchlist.
Create one now to track $MREO!
Done
Manage Watchlists
Mereo BioPharma Group PLC ADR
Health Care
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in t…
more
Conversation Volume
Last 60 days
There is not enough conversation volume about this stock
Key Opinion Leaders
Strongest 30-day focus on $MREO by total mentions
Real-time Chart
Price Chart for $MREO
Conviction History
Bullish vs Bearish Conviction over the last 30 days.
This color denotes Market Hours (US/Eastern)
There is not enough conversation volume about this stock
Thread Explorer
Explore popular threads around $MREO
There are no threads for this stock
Chart Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Rarely do we see this kind of divergence between value ($SPYV = black line) and growth ($SPYG = red line). Check it out this 5 year chart...
Go to Chart Explorer
Latest News
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Today
Past 7 days
Past 30 days
Past 60 days
Custom
Company Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Market Cap Type: Small
Close
Date,Time,Temperature
2024-03-27,16,0.06400000303983688
2024-03-27,17,0
2024-03-27,18,0
2024-03-27,19,0
2024-03-27,20,0
2024-03-27,21,0
2024-03-27,22,0
2024-03-27,23,0
2024-03-28,0,0
2024-03-28,1,0
2024-03-28,2,0
2024-03-28,3,0
2024-03-28,4,0
2024-03-28,5,0
2024-03-28,6,0
2024-03-28,7,0
2024-03-28,8,0
2024-03-28,9,0
2024-03-28,10,0
2024-03-28,11,0
2024-03-28,12,0
2024-03-28,13,0
2024-03-28,14,0
2024-03-28,15,0
2024-03-28,16,0.25
2024-03-28,17,0
2024-03-28,18,0
2024-03-28,19,0
2024-03-28,20,0
2024-03-28,21,0
2024-03-28,22,0
2024-03-28,23,0
2024-03-29,0,0
2024-03-29,1,0
2024-03-29,2,0
2024-03-29,3,0
2024-03-29,4,0
2024-03-29,5,0
2024-03-29,6,0
2024-03-29,7,0
2024-03-29,8,0
2024-03-29,9,0
2024-03-29,10,0
2024-03-29,11,0
2024-03-29,12,0
2024-03-29,13,0
2024-03-29,14,0
2024-03-29,15,0
2024-03-29,16,0.3612000048160553
2024-03-29,17,0
2024-03-29,18,0
2024-03-29,19,0
2024-03-29,20,0
2024-03-29,21,0
2024-03-29,22,0
2024-03-29,23,0
2024-03-30,0,0
2024-03-30,1,0
2024-03-30,2,0
2024-03-30,3,0
2024-03-30,4,0
2024-03-30,5,0
2024-03-30,6,0
2024-03-30,7,0
2024-03-30,8,0
2024-03-30,9,0
2024-03-30,10,0
2024-03-30,11,0
2024-03-30,12,0
2024-03-30,13,0
2024-03-30,14,0
2024-03-30,15,0
2024-03-30,16,0
2024-03-30,17,0
2024-03-30,18,0
2024-03-30,19,0
2024-03-30,20,0
2024-03-30,21,0
2024-03-30,22,0
2024-03-30,23,0
2024-03-31,0,0
2024-03-31,1,0
2024-03-31,2,0
2024-03-31,3,0
2024-03-31,4,0
2024-03-31,5,0
2024-03-31,6,0
2024-03-31,7,0
2024-03-31,8,0
2024-03-31,9,0
2024-03-31,10,0
2024-03-31,11,0
2024-03-31,12,0
2024-03-31,13,0
2024-03-31,14,0
2024-03-31,15,0
2024-03-31,16,0
2024-03-31,17,0
2024-03-31,18,0
2024-03-31,19,0
2024-03-31,20,0
2024-03-31,21,0
2024-03-31,22,0
2024-03-31,23,0
2024-04-01,0,0
2024-04-01,1,0
2024-04-01,2,0
2024-04-01,3,0
2024-04-01,4,0
2024-04-01,5,0
2024-04-01,6,0
2024-04-01,7,0
2024-04-01,8,0
2024-04-01,9,0
2024-04-01,10,0
2024-04-01,11,0
2024-04-01,12,0
2024-04-01,13,0
2024-04-01,14,0
2024-04-01,15,0
2024-04-01,16,0
2024-04-01,17,0
2024-04-01,18,0
2024-04-01,19,0
2024-04-01,20,0
2024-04-01,21,0
2024-04-01,22,0
2024-04-01,23,0
2024-04-02,0,0
2024-04-02,1,0
2024-04-02,2,0
2024-04-02,3,0
2024-04-02,4,0
2024-04-02,5,0
2024-04-02,6,0
2024-04-02,7,0
2024-04-02,8,0
2024-04-02,9,0
2024-04-02,10,0
2024-04-02,11,0
2024-04-02,12,0
2024-04-02,13,0
2024-04-02,14,0
2024-04-02,15,0
2024-04-02,16,0
2024-04-02,17,0
2024-04-02,18,0
2024-04-02,19,0
2024-04-02,20,0
2024-04-02,21,0
2024-04-02,22,0
2024-04-02,23,0
2024-04-03,0,0
2024-04-03,1,0
2024-04-03,2,0
2024-04-03,3,0
2024-04-03,4,0
2024-04-03,5,0
2024-04-03,6,0
2024-04-03,7,0
2024-04-03,8,0
2024-04-03,9,0
2024-04-03,10,0
2024-04-03,11,0
2024-04-03,12,0
2024-04-03,13,0
2024-04-03,14,0
2024-04-03,15,0
2024-04-03,16,0
2024-04-03,17,0
2024-04-03,18,0
2024-04-03,19,0
2024-04-03,20,0
2024-04-03,21,0
2024-04-03,22,0
2024-04-03,23,0
2024-04-04,0,0
2024-04-04,1,0
2024-04-04,2,0
2024-04-04,3,0
2024-04-04,4,0
2024-04-04,5,0
2024-04-04,6,0
2024-04-04,7,0
2024-04-04,8,0
2024-04-04,9,0
2024-04-04,10,0
2024-04-04,11,0
2024-04-04,12,0
2024-04-04,13,0
2024-04-04,14,0
2024-04-04,15,0
2024-04-04,16,0
2024-04-04,17,0
2024-04-04,18,0
2024-04-04,19,0
2024-04-04,20,0
2024-04-04,21,0
2024-04-04,22,0
2024-04-04,23,0
2024-04-05,0,0
2024-04-05,1,0
2024-04-05,2,0
2024-04-05,3,0
2024-04-05,4,0
2024-04-05,5,0
2024-04-05,6,0
2024-04-05,7,0
2024-04-05,8,0
2024-04-05,9,0
2024-04-05,10,0
2024-04-05,11,0
2024-04-05,12,0
2024-04-05,13,0
2024-04-05,14,0
2024-04-05,15,0
2024-04-05,16,0
2024-04-05,17,0
2024-04-05,18,0
2024-04-05,19,0
2024-04-05,20,0
2024-04-05,21,0
2024-04-05,22,0
2024-04-05,23,0
2024-04-06,0,0
2024-04-06,1,0
2024-04-06,2,0
2024-04-06,3,0
2024-04-06,4,0
2024-04-06,5,0
2024-04-06,6,0
2024-04-06,7,0
2024-04-06,8,0
2024-04-06,9,0
2024-04-06,10,0
2024-04-06,11,0
2024-04-06,12,0
2024-04-06,13,0
2024-04-06,14,0
2024-04-06,15,0
2024-04-06,16,0
2024-04-06,17,0
2024-04-06,18,0
2024-04-06,19,0
2024-04-06,20,0
2024-04-06,21,0
2024-04-06,22,0
2024-04-06,23,0
2024-04-07,0,0
2024-04-07,1,0
2024-04-07,2,0
2024-04-07,3,0
2024-04-07,4,0
2024-04-07,5,0
2024-04-07,6,0
2024-04-07,7,0
2024-04-07,8,0
2024-04-07,9,0
2024-04-07,10,0
2024-04-07,11,0
2024-04-07,12,0
2024-04-07,13,0
2024-04-07,14,0
2024-04-07,15,0
2024-04-07,16,0
2024-04-07,17,0
2024-04-07,18,0
2024-04-07,19,0
2024-04-07,20,0
2024-04-07,21,0
2024-04-07,22,0
2024-04-07,23,0
2024-04-08,0,0
2024-04-08,1,0
2024-04-08,2,0
2024-04-08,3,0
2024-04-08,4,0
2024-04-08,5,0
2024-04-08,6,0
2024-04-08,7,0
2024-04-08,8,0
2024-04-08,9,0
2024-04-08,10,0
2024-04-08,11,0
2024-04-08,12,0
2024-04-08,13,0
2024-04-08,14,0
2024-04-08,15,0
2024-04-08,16,0
2024-04-08,17,0
2024-04-08,18,0
2024-04-08,19,0
2024-04-08,20,0
2024-04-08,21,0
2024-04-08,22,0
2024-04-08,23,0
2024-04-09,0,0
2024-04-09,1,0
2024-04-09,2,0
2024-04-09,3,0
2024-04-09,4,0
2024-04-09,5,0
2024-04-09,6,0
2024-04-09,7,0
2024-04-09,8,0
2024-04-09,9,0
2024-04-09,10,0
2024-04-09,11,0
2024-04-09,12,0
2024-04-09,13,0
2024-04-09,14,0
2024-04-09,15,0
2024-04-09,16,0
2024-04-09,17,0
2024-04-09,18,0
2024-04-09,19,0
2024-04-09,20,0
2024-04-09,21,0
2024-04-09,22,0
2024-04-09,23,0
2024-04-10,0,0
2024-04-10,1,0
2024-04-10,2,0
2024-04-10,3,0
2024-04-10,4,0
2024-04-10,5,0
2024-04-10,6,0
2024-04-10,7,0
2024-04-10,8,0
2024-04-10,9,0
2024-04-10,10,0
2024-04-10,11,0
2024-04-10,12,0
2024-04-10,13,0
2024-04-10,14,0
2024-04-10,15,0
2024-04-10,16,0
2024-04-10,17,0
2024-04-10,18,0
2024-04-10,19,0
2024-04-10,20,0
2024-04-10,21,0
2024-04-10,22,0
2024-04-10,23,0
2024-04-11,0,0
2024-04-11,1,0
2024-04-11,2,0
2024-04-11,3,0
2024-04-11,4,0
2024-04-11,5,0
2024-04-11,6,0
2024-04-11,7,0
2024-04-11,8,0
2024-04-11,9,0
2024-04-11,10,0
2024-04-11,11,0
2024-04-11,12,0
2024-04-11,13,0
2024-04-11,14,0
2024-04-11,15,0
2024-04-11,16,0
2024-04-11,17,0
2024-04-11,18,0
2024-04-11,19,0
2024-04-11,20,0
2024-04-11,21,0
2024-04-11,22,0
2024-04-11,23,0
2024-04-12,0,0
2024-04-12,1,0
2024-04-12,2,0
2024-04-12,3,0
2024-04-12,4,0
2024-04-12,5,0
2024-04-12,6,0
2024-04-12,7,0
2024-04-12,8,0
2024-04-12,9,0
2024-04-12,10,0
2024-04-12,11,0
2024-04-12,12,0
2024-04-12,13,0
2024-04-12,14,0
2024-04-12,15,0
2024-04-12,16,0
2024-04-12,17,0
2024-04-12,18,0
2024-04-12,19,0
2024-04-12,20,0
2024-04-12,21,0
2024-04-12,22,0
2024-04-12,23,0
2024-04-13,0,0
2024-04-13,1,0
2024-04-13,2,0
2024-04-13,3,0
2024-04-13,4,0
2024-04-13,5,0
2024-04-13,6,0
2024-04-13,7,0
2024-04-13,8,0
2024-04-13,9,0
2024-04-13,10,0
2024-04-13,11,0
2024-04-13,12,0
2024-04-13,13,0
2024-04-13,14,0
2024-04-13,15,0
2024-04-13,16,0
2024-04-13,17,0
2024-04-13,18,0
2024-04-13,19,0
2024-04-13,20,0
2024-04-13,21,0
2024-04-13,22,0
2024-04-13,23,0
2024-04-14,0,0
2024-04-14,1,0
2024-04-14,2,0
2024-04-14,3,0
2024-04-14,4,0
2024-04-14,5,0
2024-04-14,6,0
2024-04-14,7,0
2024-04-14,8,0
2024-04-14,9,0
2024-04-14,10,0
2024-04-14,11,0
2024-04-14,12,0
2024-04-14,13,0
2024-04-14,14,0
2024-04-14,15,0
2024-04-14,16,0
2024-04-14,17,0
2024-04-14,18,0
2024-04-14,19,0
2024-04-14,20,0
2024-04-14,21,0
2024-04-14,22,0
2024-04-14,23,0
2024-04-15,0,0
2024-04-15,1,0
2024-04-15,2,0
2024-04-15,3,0
2024-04-15,4,0
2024-04-15,5,0
2024-04-15,6,0
2024-04-15,7,0
2024-04-15,8,0
2024-04-15,9,0
2024-04-15,10,0
2024-04-15,11,0
2024-04-15,12,0
2024-04-15,13,0
2024-04-15,14,0
2024-04-15,15,0
2024-04-15,16,0
2024-04-15,17,0
2024-04-15,18,0
2024-04-15,19,0
2024-04-15,20,0
2024-04-15,21,0
2024-04-15,22,0
2024-04-15,23,0
2024-04-16,0,0
2024-04-16,1,0
2024-04-16,2,0
2024-04-16,3,0
2024-04-16,4,0
2024-04-16,5,0
2024-04-16,6,0
2024-04-16,7,0
2024-04-16,8,0
2024-04-16,9,0
2024-04-16,10,0
2024-04-16,11,0
2024-04-16,12,0
2024-04-16,13,0
2024-04-16,14,0
2024-04-16,15,0
2024-04-16,16,0
2024-04-16,17,0
2024-04-16,18,0
2024-04-16,19,0
2024-04-16,20,0
2024-04-16,21,0
2024-04-16,22,0
2024-04-16,23,0
2024-04-17,0,0
2024-04-17,1,0
2024-04-17,2,0
2024-04-17,3,0
2024-04-17,4,0
2024-04-17,5,0
2024-04-17,6,0
2024-04-17,7,0
2024-04-17,8,0
2024-04-17,9,0
2024-04-17,10,0
2024-04-17,11,0
2024-04-17,12,0
2024-04-17,13,0
2024-04-17,14,0
2024-04-17,15,0
2024-04-17,16,0
2024-04-17,17,0
2024-04-17,18,0
2024-04-17,19,0
2024-04-17,20,0
2024-04-17,21,0
2024-04-17,22,0
2024-04-17,23,0
2024-04-18,0,0
2024-04-18,1,0
2024-04-18,2,0
2024-04-18,3,0
2024-04-18,4,0
2024-04-18,5,0
2024-04-18,6,0
2024-04-18,7,0
2024-04-18,8,0
2024-04-18,9,0
2024-04-18,10,0
2024-04-18,11,0
2024-04-18,12,0
2024-04-18,13,0
2024-04-18,14,0
2024-04-18,15,0
2024-04-18,16,0
2024-04-18,17,0
2024-04-18,18,0
2024-04-18,19,0
2024-04-18,20,0
2024-04-18,21,0
2024-04-18,22,0
2024-04-18,23,0
2024-04-19,0,0
2024-04-19,1,0
2024-04-19,2,0
2024-04-19,3,0
2024-04-19,4,0
2024-04-19,5,0
2024-04-19,6,0
2024-04-19,7,0
2024-04-19,8,0
2024-04-19,9,0
2024-04-19,10,0
2024-04-19,11,0.12800000607967377